In this study, we described the family tree of a patient with PVOD with a rare compound heterozygous EIF2AK4 mutation, who exhibited a good response to targeted therapeutics, different from most patients with PVOD. Here, EIF2AK4 is linked to pulmonary venoocclusive disease.